JP2005041877A - 香粧品組成物 - Google Patents
香粧品組成物 Download PDFInfo
- Publication number
- JP2005041877A JP2005041877A JP2004222674A JP2004222674A JP2005041877A JP 2005041877 A JP2005041877 A JP 2005041877A JP 2004222674 A JP2004222674 A JP 2004222674A JP 2004222674 A JP2004222674 A JP 2004222674A JP 2005041877 A JP2005041877 A JP 2005041877A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- composition
- compound
- hair
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 201000004384 Alopecia Diseases 0.000 claims abstract description 18
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 239000002537 cosmetic Substances 0.000 claims abstract description 10
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 3
- 150000001875 compounds Chemical group 0.000 claims description 35
- 208000024963 hair loss Diseases 0.000 claims description 9
- 230000003676 hair loss Effects 0.000 claims description 9
- -1 retinoids Substances 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 6
- 150000003230 pyrimidines Chemical class 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 230000003659 hair regrowth Effects 0.000 claims description 3
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 claims description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000002280 anti-androgenic effect Effects 0.000 claims description 2
- 239000000051 antiandrogen Substances 0.000 claims description 2
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 abstract description 8
- 150000002303 glucose derivatives Chemical class 0.000 abstract description 4
- HEGOZZGDTGYRGM-OIMNJJJWSA-N [(2r,3r,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexyl] octanoate Chemical compound CCCCCCCC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O HEGOZZGDTGYRGM-OIMNJJJWSA-N 0.000 abstract description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 2
- 239000008103 glucose Substances 0.000 abstract description 2
- 210000004209 hair Anatomy 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 7
- 210000004761 scalp Anatomy 0.000 description 7
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000002453 shampoo Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000003779 hair growth Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- HXPDCYVXFCSNQJ-AAZCQSIUSA-N [(2r,3r,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O HXPDCYVXFCSNQJ-AAZCQSIUSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- VKPSKYDESGTTFR-UHFFFAOYSA-N 2,2,4,6,6-pentamethylheptane Chemical compound CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 description 1
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 1
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical compound N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 description 1
- 108010023590 APG350 Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 150000000780 D-glucose derivatives Chemical class 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920013806 TRITON CG-110 Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- FBFVXPATMKWDBP-SJXGUFTOSA-N [(2r,3r,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexyl] decanoate Chemical compound CCCCCCCCCC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O FBFVXPATMKWDBP-SJXGUFTOSA-N 0.000 description 1
- FTCGZXFZNUEELT-BURFUSLBSA-N [(2r,3r,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O FTCGZXFZNUEELT-BURFUSLBSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-M all-trans-retinoate Chemical compound [O-]C(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-M 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 125000002714 alpha-linolenoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical group OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 150000008049 diazo compounds Chemical class 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- MGLDCXPLYOWQRP-UHFFFAOYSA-N eicosa-5,8,11,14-tetraynoic acid Chemical compound CCCCCC#CCC#CCC#CCC#CCCCC(O)=O MGLDCXPLYOWQRP-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 150000008273 hexosamines Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940051295 hexylnicotinate Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004232 linoleic acid Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960001238 methylnicotinate Drugs 0.000 description 1
- IYIYMCASGKQOCZ-DJRRULDNSA-N motretinide Chemical compound CCNC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C IYIYMCASGKQOCZ-DJRRULDNSA-N 0.000 description 1
- 229960005406 motretinide Drugs 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
【解決手段】アルキルポリグリコシドおよび(または)グルコースのO−アシル化誘導体を香粧品的または医薬品的に使用する香粧品組成物。前記アルキルポリグルコシドは構造式R1−O−(C6H10O5)xH(式中、R1はアルキルもしくはアルケニル基またはこれらの混合物であり、xは1〜15)であり、また、グルコースのO−アシル化誘導体は、6−O−オクタノイル−D−グルコース等である。
【選択図】なし
Description
の構造式に該当する式(I)
R1(C6H10O5)xH
(これらの式中、R1は非分枝または分枝のC8〜C24鎖を有するアルキルまたはアルケニル基あるいはこれらの基の混合基を表わし、xは1〜15の数である)に相当する化合物および(または)式(III)
(式中、R2は炭素原子7〜19個を有する飽和または不飽和の直鎖炭化水素鎖を表わしまたR3は水素またはC1〜C4低級アルキル基を表わす)に相当する化合物を使用するが、式(I)の化合物はピリミジン誘導体と組合わせては使用しない。
・一層特定的にはC1〜C6アルキルニコチネート、特にメチル、ヘキシルおよびベンジルニコチネートを含めてのニコチン酸エステル、など;
・従来技術において周知なステロイドおよび非ステロイド抗炎症剤、特にハイドロコーチゾン、その塩およびその誘導体、ニフルミン酸、など;
・トレチノイン、イソトレチノイン、レチノールまたはビタミンAとしても知られる全トランス−レチノイン酸のようなレチノイドおよびその誘導体、例えばアセテート、パルミテートまたはプロピオネート、モトレチニド、エトレチネートおよび亜鉛全トランス−レチノエート;
・ピリミジン誘導体例えば「minoxidil」の名でも知られ、米国特許第4,139,619号明細書中に記載されており、式(III)の化合物としてのみ存在する6−アミノ−1,2−ジヒドロ−1−ヒドロキシ−2−イミノ−4−ピペリジノビリミジン;
・マクロライド、ピラノシドおよびテトラサイクリン、そして特にエリスロマイシンから選択する抗菌剤;
・シナリジンおよびジルチアゼムのようなカルシウム拮抗剤;
・エストリオールもしくはその類縁体あるいはチロキシンおよびその塩;
・抗アンドロゲン例えばオキセンドロン、スピロノラクトンおよびジエチルスチルベストロール;
・OHラジカル捕捉剤例えばジメチルスルホキシド
と組合わされてよい。
a) 式(1)
(式中、nは2〜16である)に相当する毛管粘度が500cpsより低いイソパラフィン;
b) 式(1)のイソパラフィンと式(2)
(式中、mは18以上、望ましくは18〜40である)を有するイソパラフィンとの、毛管粘度が500cpsより低い混合物;
c) 例えば、エチルコーポレーション社により「ETHYLFLO 362 NF、364NF、366NF」の名で発売の、40℃での粘度が40cstより低い製品のようなポリデセン。
PERSPERSE社により「PERMETHYL 99A、101A、102Aまたは104A」の名で発売の製品あるいはICI社により発売のARLAMOL HD製品をあげることができる。
下記の組成の非リンスローションを調製する:
・ヘンケル社によりAPG300の名で有効成分50%をもつ
ものとして発売のアルキル(C9/C10/C11,20:40
:40)ポリグリコシド 有効成分3g
・エチルアルコール 30.55g
・香料 十分な量
・水 全体を100gとする量
下記の組成のシャンプーを調製する:
・ヘンケル社によりAPG600の名で有効成分50%をもつ
ものとして発売のアルキル(C12/C14/C16,68:26
:6)ポリグリコシド 有効成分20g
・アクアロン社によりKLUCEL Gの名で発売のヒドロキシプロ
ピルセルロース(分子量300,000) 0.5g
・エチルアルコール 十分な量
・保存剤、香料 十分な量
・水 全体を100gとする量
下記の組成の非リンスローションを調製する:
・ヘンケル社によりAPG300の名で有効成分50%をもつ
ものとして発売のアルキル(C9/C10/C11,20:40
:40)ポリグリコシド 有効成分5g
・プロピレングリコール 22.8g
・エチルアルコール 55.1g
・水 全体を100gとする量
下記の組成をもつ非リンスローションを調製する:
・6−O−オクタノイル−D−グルコース 5g
・プロピレングリコール 22.8g
・エチルアルコール 55.1g
・水 全体を100gとする量
下記の組成をもつ非リンスローションを調製する:
・6−O−オレオイル−D−グルコース 2.5g
・プロピレングリコール 22.8g
・エチルアルコール 55.1g
・水 全体を100gとする量
下記の組成の非リンスローションを調製する:
・ヘンケル社によりAPG500の名で有効成分50%をもつ
ものとして発売のアルキル(C12〜C13)ポリグリコシド 有効成分5g
・プロピレングリコール 22.8g
・エチルアルコール 55.1g
・水 全体を100gとする量
下記の組成の非リンスローションを調製する:
・6−O−オクタノイル−D−グルコース 2.5g
・ヘンケル社によりAPG500の名で有効成分50%をもつ
ものとして発売のアルキル(C12〜C13)グルコシド 有効成分2.5g
・プロピレングリコール 22.8g
・エチルアルコール 55.1g
・水 全体を100gとする量
下記の組成をもつ、脱毛を阻止するためのシャンプーを調製する:
・ヘンケル社によりAPG300の名で有効成分50%をもつ
ものとして発売のアルキル(C9/C10/C11,20:40
:40)ポリグリコシド 有効成分15g
・ローヌプーラン社によりKELTROL Tの名で発売のキサンタン
ガム 1g
・ICI社によりARLAMOL HDの名で発売の合成油 2g
・保存剤、香料 十分な量
・HCl pHを7とする量
・水 全体を100gとする量
Claims (6)
- 毛髪の再成長および(または)脱毛の停止に関する活性を改良する薬剤をさらに含有する、請求の範囲第1項記載の組成物。
- 毛髪の再成長に関する活性を改善する薬剤を、ニコチン酸エステル、ステロイドまたは非ステロイド抗炎症剤、レチノイド、抗バクテリア剤、カルシウム拮抗剤、ホルモン、抗アンドロゲン、−OH基捕捉剤、及び組成物が式(III)の化合物を含有する場合はピリミジン誘導体のうちから選択する、請求の範囲第2項に記載の組成物。
- 組成物の全重量に対して0.1〜10重量%の割合の式(I)の化合物および(または)式(III)の化合物を含有する組成物であって、その適用後にリンスを行なわない、請求の範囲第1項から第4項のいずれか1項に記載の組成物。
- 組成物の全重量に対して1〜30重量%の割合の式(I)の化合物および(または)式(III)の化合物を含有する組成物であって、その適用後にリンスを行う、請求の範囲第1項から第4項のいずれか1項に記載の組成物。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9110060A FR2680103B1 (fr) | 1991-08-07 | 1991-08-07 | Utilisation en cosmetique ou en pharmacie d'alkylpolyglycosides et/ou de derives o-acyles du glucose pour le traitement de la chute des cheveux. |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1993503346 Division | 1992-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2005041877A true JP2005041877A (ja) | 2005-02-17 |
Family
ID=9416005
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5503346A Pending JPH07500578A (ja) | 1991-08-07 | 1992-08-05 | 脱毛を治療するためのアルキルポリグリコシドおよび(または)グルコースのo−アシル化誘導体の使用 |
JP2004222674A Pending JP2005041877A (ja) | 1991-08-07 | 2004-07-30 | 香粧品組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5503346A Pending JPH07500578A (ja) | 1991-08-07 | 1992-08-05 | 脱毛を治療するためのアルキルポリグリコシドおよび(または)グルコースのo−アシル化誘導体の使用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US6203783B1 (ja) |
EP (1) | EP0663812B1 (ja) |
JP (2) | JPH07500578A (ja) |
DE (1) | DE69214299T2 (ja) |
ES (1) | ES2092695T3 (ja) |
FR (1) | FR2680103B1 (ja) |
WO (1) | WO1993002657A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9204175D0 (en) * | 1992-02-27 | 1992-04-08 | Unilever Plc | Cleansing composition |
DE4327700A1 (de) * | 1993-08-19 | 1995-02-23 | Henkel Kgaa | Haarbehandlungsmittel |
US20020165168A1 (en) * | 1995-12-16 | 2002-11-07 | Joachim Bunger | Use of sugar derivatives as antimicrobial, antimycotic and/or antiviral active substances |
US6207694B1 (en) * | 1998-07-27 | 2001-03-27 | Howard Murad | Pharmaceutical compositions and methods for managing scalp conditions |
US7763587B2 (en) * | 2002-06-13 | 2010-07-27 | L'oreal S.A. | Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process |
DE60316221T2 (de) * | 2002-06-13 | 2008-06-12 | L'oreal | Glucosederivat von Vitamin F, Zusammensetzungen, die es enthalten, Verwendungen und Herstellungsverfahren |
FR2840903B1 (fr) * | 2002-06-13 | 2005-01-28 | Oreal | Derive de glucose et de vitamine f, compositions le comprenant et utilisations pour ameliorer l'etat des poils et des cheveux |
DE10260955A1 (de) * | 2002-12-20 | 2004-07-08 | Henkel Kgaa | Verwendung von Steroidsulfatase-Inhibitoren zur Verminderung von Haarausfall |
FR2881647B1 (fr) * | 2005-02-08 | 2007-03-30 | Oreal | Composition cosmetique ou dermatologique contenant un derive de glucose et de vitamine f et un tensioactif specifique |
US20060177403A1 (en) * | 2005-02-08 | 2006-08-10 | L'oreal | Cosmetic/dermatological compositions comprising a derivative of glucose and of vitamin F and A specific surfactant |
FR2918270A1 (fr) * | 2007-07-03 | 2009-01-09 | Claude Boucher | Utilisation d'une emulsion naturelle,stable pour usages cosmetiques,pharmaceutique |
FR2991873B1 (fr) * | 2012-06-15 | 2014-08-29 | Oreal | Composition comprenant un ester d'acide pyridine dicarboxylique et un ester de glucose et d'acide gras, procede et utilisation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4139619A (en) | 1976-05-24 | 1979-02-13 | The Upjohn Company | 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth |
LU84416A1 (fr) * | 1982-10-11 | 1984-05-10 | Oreal | Composition de nettoyage doux |
FR2581542B1 (fr) | 1985-05-07 | 1988-02-19 | Oreal | Compositions topiques destinees au traitement de la peau a base de derives de l'acide salicylique |
GB8519416D0 (en) | 1985-08-01 | 1985-09-04 | Unilever Plc | Oligosaccharides |
LU86429A1 (fr) | 1986-05-16 | 1987-12-16 | Oreal | Compositions cosmetiques renfermant un polymere cationique et un polymere anionique comme agent epaississant |
LU87323A1 (fr) * | 1988-08-25 | 1990-03-13 | Oreal | Composition pour induire et stimuler la croissance des cheveux et/ou freiner leur chute,a base d'alkylpolyglycoside et d'un derive de pyrimidine |
JP2775915B2 (ja) * | 1989-11-06 | 1998-07-16 | ライオン株式会社 | 非イオン性界面活性剤 |
JPH03157349A (ja) * | 1989-11-14 | 1991-07-05 | Lion Corp | 乳化組成物 |
-
1991
- 1991-08-07 FR FR9110060A patent/FR2680103B1/fr not_active Expired - Fee Related
-
1992
- 1992-08-05 JP JP5503346A patent/JPH07500578A/ja active Pending
- 1992-08-05 WO PCT/FR1992/000773 patent/WO1993002657A1/fr active IP Right Grant
- 1992-08-05 DE DE69214299T patent/DE69214299T2/de not_active Expired - Lifetime
- 1992-08-05 ES ES92918038T patent/ES2092695T3/es not_active Expired - Lifetime
- 1992-08-05 EP EP92918038A patent/EP0663812B1/fr not_active Expired - Lifetime
-
1996
- 1996-09-09 US US08/709,666 patent/US6203783B1/en not_active Expired - Fee Related
-
2004
- 2004-07-30 JP JP2004222674A patent/JP2005041877A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE69214299D1 (de) | 1996-11-07 |
ES2092695T3 (es) | 1996-12-01 |
EP0663812B1 (fr) | 1996-10-02 |
FR2680103B1 (fr) | 1993-10-29 |
JPH07500578A (ja) | 1995-01-19 |
FR2680103A1 (fr) | 1993-02-12 |
DE69214299T2 (de) | 1997-02-20 |
US6203783B1 (en) | 2001-03-20 |
WO1993002657A1 (fr) | 1993-02-18 |
EP0663812A1 (fr) | 1995-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2880125B2 (ja) | 髪の成長の促進または刺激および/または抜毛防止薬剤 | |
JP2005041877A (ja) | 香粧品組成物 | |
JP2962558B2 (ja) | 化粧料 | |
JP2003521452A (ja) | 活性薬剤用の局所的供給システム | |
KR20010049428A (ko) | 신규 국소 제형 | |
JP2003510241A (ja) | 油っぽく/てかてか光る皮膚を調節する塗布用組成物 | |
JPS6341364B2 (ja) | ||
JPH0317804B2 (ja) | ||
JP2814085B2 (ja) | 養毛料 | |
JP4627107B2 (ja) | 毛髪外用剤組成物 | |
HUT72623A (en) | Composition for stimulating of hair growth and/or inhibiting of falling hair (alopencia) containing alfa-pyron derivatives and use of the compositions | |
JP2009242397A (ja) | イミド過カルボン酸誘導体およびn−アシル化アミノ酸エステルを含有する化粧用組成物 | |
JP5911664B2 (ja) | 特定の界面活性剤と、グルコースおよびビタミンfの誘導体とを含有する化粧品または皮膚科学的組成物 | |
JPH06502161A (ja) | レチノイド浸透作用エンハンサーを含む局所用組成物 | |
JP2003155218A (ja) | 養育毛組成物 | |
JPH04234805A (ja) | 毛髪に適用するための化粧品組成物の製造方法、この方法 により得られる組成物及び前記組成物を使う化粧処理方法 | |
EP0813859A2 (de) | Haarbehandlungsmittel mit Depotwirkung | |
JPS6115816A (ja) | 頭髪化粧料 | |
JP2003321330A (ja) | 養育毛組成物 | |
JP2009242396A (ja) | マデカッソシド及び/またはターミノロシド並びにアルギニン及び/またはその塩及び/またはその誘導体の組み合わせを含む組成物;ヒトケラチン線維の成長を誘導及び/または刺激するための、及び/またはヒトケラチン線維の損失を予防するための前記組み合わせの使用 | |
JPH10279437A (ja) | 頭髪用化粧料 | |
WO1992009258A1 (fr) | Nouvelle utilisation d'un compose d'alcanamidoammonium | |
US5985841A (en) | Deoxyglucopyranoside compounds for inducing/stimulating hair growth and/or retarding hair loss | |
JP2871764B2 (ja) | 化粧料 | |
JP2566792B2 (ja) | 発毛、養毛促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060620 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060919 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060922 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080401 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081031 |